Thursday, June 30, 2022


Bal Johal Is Appointed New Director of Research and Development at Owen Mumford

Latest Posts

Kyowa Kirin Expands License Agreement with Synaffix and Takes Exclusive Target Rights Based on Latest Positive ADC Data

The technology licensed from Synaffix include GlycoConnect™, HydraSpace™, and multiple toxSYN™ linker-payloads, which allow for the drug-to-antibody ratio (DAR) to be tailored to 1, 2 or 4 to optimize the therapeutic index of the ADC.

Ingenza Awarded Government Funding

Ingenza advises the project aims to develop a novel CO2 conversion technology, which will capture industrial CO2 emissions and convert them into formate, a versatile chemical that can be used across various industries, including pharmaceuticals and agriculture.

MultiOmic Health and Mesh Bio Partner to Use AI to Develop Precision Medicines & Diagnostics for Chronic Metabolic Disease

MultiOmic Health advises the partnership will provide access to data from patient populations in Asia that have historically been underrepresented in chronic metabolic disease studies.

BD Launches Combination Test for COVID-19, Influenza A/B and Respiratory Syncytial Virus

BD notes the test uses a single nasal swab or a single nasopharyngeal swab sample to determine if a patient has COVID-19 or the flu or RSV. It helps eliminate the need for multiple tests or doctor visits and can help clinicians to implement the right treatment plan quickly.

Bal Johal brings a wealth of experience in the pharmaceutical and medical device sector, covering a range of therapeutic areas and dosage forms, most recently working as vice president of product development, quality, regulatory and medical with Circassia.

Prior to this, Bal Johal had roles within research and development at GlaxoSmithKline, Pfizer and Mundipharma Research Ltd.

Research and development has always been at the heart of Owen Mumford’s unique offer and represents a major pillar in the company’s strategic direction and development. The appointment of Johal into this pivotal role will enhance the quality and strength of the company’s existing pipeline. It also secures a well-defined path to deliver new ambitions in innovation, sustainable product design, life-cycle analysis and increased positive impact on healthcare professional and patient experience.

“We welcome Bal very warmly into our business,” said Jarl Severn, Managing Director at Owen Mumford. “She has the background, experience and drive to continue to accelerate the innovation and forward-thinking that will see us achieve ambitious growth and set us apart from the competition.”

Commenting on her appointment, Bal Johal said, “To join Owen Mumford at this time is very exciting. With a combination of progress already made and some very talented people within the organisation, I can see that we will be able to deliver a high standard of success and innovation that will have a truly positive impact.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine